Pharmafile Logo

Pepperl+Fuchs GB Limited

Pepperl+Fuchs is a leading developer and manufacturer of electronic sensors and components for the global automation market. Continuous innovation, enduring quality, and steady growth guarantees continued success, since more than 60 years. Pepperl+Fuchs employs 5,200 people worldwide and has manufacturing facilities in Germany, USA, Singapore, Hungary, Indonesia and Vietnam, most of them ISO 9001 certified.

This is a FREE LISTING on PMHUB

Below are full profiles from other companies in related areas

No items found

Company Details

77 Ripponden Road, Oldham, Lancashire, OL1 4EL, United Kingdom
+44 (0)161 6336431

 Latest Content from PMHub 

Promoting enthusiasm and scientific expertise at Porterhouse Medical

Porterhouse Medical Group is delighted to announce that Beth Wynne-Evans has been promoted to Senior Medical Writer.Beth makes an important and vibrant contribution to our scientific services solutions at Porterhouse....

Top 10 Most Important Advisor Questions

Impetus Digital shares its Top 10 list of the most important advisor questions.

Four Health announces a pair of internal promotions

Richard Springham and Kelly Smith will both take on managing director roles

Meet two of OPEN Health’s practices – Peloton Advantage and Pharmerit at MAPS 2020

Press Releases | March 3, 2020 | OPEN Health

Turning scientific knowledge and data into evidence

Porterhouse Medical Group strengthens its leadership team in the US

The Porterhouse Medical Group is delighted to welcome Julia (Wenniger) Van Diver, who joins the team as Vice President, Scientific Services, at Porterhouse Medical US.Julia has a BA (Hons) in English...

Delivering change through better rare disease communications

OPEN Health’s Richard Jones, Gemma Allen and Charlotte Richards discuss how pharma can utilise tools, channels and stakeholders to deliver change and enable better outcomes.

The ALS patient journey

Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...